AbbVie Expands Immunology Portfolio in the European Union

AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI^® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis

AbbVie (NYSE: ABBV) has announced that the European Commission (EC) has approved SKYRIZI.^® (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX). This is for the treatment of active psoriatic arthritis in adults who have had an inadequate response. Or those who have been intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Marking the second indication for risankizumab, the Marketing Authorization will be valid in all member states of the European Union. This is as well as Iceland, Liechtenstein, Norway and Northern Ireland.